President, Research and Development; Nimbus Therapeutics
Peter Tummino, Ph.D. is President, Research and Development at Nimbus Therapeutics, where he leads the discovery, nonclinical and clinical groups. Since joining Nimbus as Chief Scientific Officer in 2019, he has been part of the leadership team. In his time at Nimbus, the company has successfully progressed the TYK2 inhibitor NDI-4858 through Phase 2 trials for psoriasis and other immunology indications, advanced the HPK1 inhibitor NDI-101150 through Phase 1b trials in solid tumors and initiated Phase 1 trials for the WRN inhibitor NDI-219216 in MSI-high solid tumors.
Peter brings more than 30 years of experience in drug discovery across a range of therapeutic areas. Prior to joining Nimbus, he served as Vice President, Global Head of Lead Discovery at Janssen Pharmaceuticals, where he lead global discovery operations across multiple therapeutic areas. He held leadership roles at GlaxoSmithKline (GSK), including Head of Biology for the Cancer Epigenetics Discovery Performance Unit where he helped progress first-in-class epigenetic agents into oncology clinical trials. His contributions at GSK included the discovery and progression of several clinical candidates, including the approved oncology drugs dabrafenib (BRAF inhibitor), trametinib (MEK inhibitor) and daprodustat for chronic kidney disease. Earlier, he held scientific positions of increasing responsibility at Warner-Lambert/Parke-Davis, AstraZeneca and Millennium Pharmaceuticals. He has published 85 peer-reviewed journal articles with more than 15,000 citations. Peter earned his BS in Chemistry from the University of Massachusetts and his Ph.D. from the Department of Biological Chemistry at the University of Michigan. He completed a postdoctoral fellowship at Warner-Lambert/Parke-Davis.